about
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAARTRecent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central ItalyMutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitorsHigh sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.The HIV type 1 epidemic in Bulgaria involves multiple subtypes and is sustained by continuous viral inflow from West and East European countries.Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing.Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitorsMolecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in ItalyGenotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia.Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy.Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA.Impact of pre-therapy viral load on virological response to modern first-line HAART.Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains.Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines.High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians.HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection.Circulation of HIV-1 CRF02_AG among MSM population in central Italy: a molecular epidemiology-based studyReliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score.Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir.Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test.The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: evidences from literature.Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.Genetic diversity of HIV type 1 in Montenegro.Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon.Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy.Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
P50
Q28542548-5C6F9214-8FE3-4E3F-A803-5BDEE48850F3Q28547222-FC19CF13-2C7C-4DF7-B2A9-DB121DA45DDEQ33603586-EEEDDFAB-ECAC-48E8-A6EA-710E02F3B004Q33770040-D68F4EAD-2A71-42C5-8C0F-3D8A406AFEAFQ33911980-1D56E43F-164D-4C2E-A04F-696FC1EBEB07Q34080833-7AF6561E-ABF7-4837-9D70-999D2030BEBFQ34083250-4280700F-02C9-4A60-89BF-CE6CD0EAE20CQ34558508-9511B086-49D5-4CEF-AFB6-3F48F1C46D2DQ34717615-F14B029C-3F6C-491C-8B7A-45AF25CD5344Q35508265-059083EB-9A5C-4147-A2F9-D459D8645DF6Q35968753-6DB9E26D-6A81-4852-B253-606EF043E443Q36099251-152AE365-AA52-44D5-BE69-F150571DD650Q36250342-4BC0DD67-BFB6-41C1-9574-6C288F0AA17AQ37077610-F9D306BD-7496-4227-A1CE-38BEA035FE4AQ38379004-4F9BF7BE-A060-4369-95F4-5CD17F930DEEQ38427973-097B38E7-0BE2-4EFC-9A4B-ABADDA2972C9Q39648233-5945FAF3-6D6D-43D3-BA40-85C3ACCFEA30Q40137561-63EFC70F-1085-4DE0-B0F4-04CD75CA8A07Q40401616-715653F2-0FC2-419E-B09B-3FF3928ACBC9Q40573390-DC88A517-D571-4FDC-9BBB-139FC72D6106Q40812700-77F7FECB-E945-4087-9ED5-3AFDC256A5E4Q40896891-0ED2CBE4-7656-4EAB-BB96-808F3F94B674Q40974998-50CFBF8C-E6B0-4BC4-A43E-273D3F07CDCDQ41465991-F368FC22-FF0C-44C2-B29C-414D64ACFAA2Q41553085-FC69EC5C-B781-4FC0-BA3F-55A2557A3EF4Q41632541-E39C1642-8D60-4C8C-AA57-A2065CFB55C6Q41812338-61909787-DA23-4671-9B1F-6A375652621DQ42243024-6D5EC603-7D4F-4712-A82F-B9632E06EC90Q42839647-6C1F2F18-EB50-4606-B4D6-4ED2C89A7471Q42925586-DFF2830F-CC36-4789-9EBD-764FB6D81DDBQ43189982-C79FA17B-D30A-449A-A2DA-D626BC0E137EQ43207719-78B00609-0BC6-44B5-8AB1-8AB3C0B3B942Q43875709-E41CB32E-321D-475C-BC92-D8D11BCD0E25Q44113439-164FF8D6-3501-4EDB-A817-9FDBC7A4CB23Q45222313-24D94400-96BD-4FF3-8B5D-08071F71E66BQ45367650-D31ABFC8-A5DB-425C-8456-5D9214193242Q45720065-D076D3A8-5023-4AF7-BB54-FD72B230D1C1Q46128525-696450B9-6642-4802-AB72-AAB89BE60EF8Q46147193-CA284DD4-BBAD-4F28-ABCA-3C9C6257E7F1Q46230871-79B16D62-2D9A-433E-9F26-8218EB93C845
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maria M Santoro
@ast
Maria M Santoro
@en
Maria M Santoro
@es
Maria M Santoro
@nl
type
label
Maria M Santoro
@ast
Maria M Santoro
@en
Maria M Santoro
@es
Maria M Santoro
@nl
prefLabel
Maria M Santoro
@ast
Maria M Santoro
@en
Maria M Santoro
@es
Maria M Santoro
@nl
P106
P1153
57194235764
P21
P31
P496
0000-0002-6228-1114